114.00
Schlusskurs vom Vortag:
$114.45
Offen:
$114.47
24-Stunden-Volumen:
612.55K
Relative Volume:
0.51
Marktkapitalisierung:
$11.37B
Einnahmen:
$2.24B
Nettoeinkommen (Verlust:
$385.90M
KGV:
30.56
EPS:
3.73
Netto-Cashflow:
$440.10M
1W Leistung:
+3.57%
1M Leistung:
-2.99%
6M Leistung:
-0.92%
1J Leistung:
-17.29%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NBIX
Neurocrine Biosciences Inc
|
114.00 | 11.37B | 2.24B | 385.90M | 440.10M | 3.73 |
![]()
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | Fortgesetzt | Citigroup | Neutral |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-08-21 | Bestätigt | Mizuho | Neutral |
2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-10-11 | Eingeleitet | UBS | Buy |
2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
2022-06-06 | Fortgesetzt | Jefferies | Buy |
2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-09-23 | Fortgesetzt | Needham | Hold |
2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
2021-05-18 | Fortgesetzt | Goldman | Neutral |
2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
2021-02-02 | Eingeleitet | Raymond James | Outperform |
2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
2020-06-09 | Eingeleitet | Wedbush | Outperform |
2020-03-06 | Eingeleitet | Citigroup | Buy |
2020-02-27 | Eingeleitet | Barclays | Equal Weight |
2020-02-24 | Eingeleitet | William Blair | Outperform |
2020-02-06 | Eingeleitet | Mizuho | Neutral |
2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
2019-06-05 | Eingeleitet | Guggenheim | Neutral |
2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2019-02-06 | Bestätigt | BofA/Merrill | Buy |
2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-12-13 | Eingeleitet | Goldman | Buy |
2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga
Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView
Tardive Dyskinesia Treatment Market Expands with New Drug - openPR
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo Finance
Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter
Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - PR Newswire
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Neurocrine at Stifel 2025 CNS Forum: Strategic Insights and Challenges - Investing.com
Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires? - Insider Monkey
Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza - Nasdaq
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions - StockTitan
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com - Defense World
Schizophrenia Treatment Market Size Report 2034 | Novartis - openPR
US Bancorp DE Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
RBC Capital cuts Neurocrine Bio. stock target to $139 from $148 - Investing.com India
Trend Tracker for (NBIX) - Stock Traders Daily
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum - PR Newswire
RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating - Marketscreener.com
Neurocrine Leadership Reveals Next Steps in CNS Drug DevelopmentKey Presentation Coming - StockTitan
Smartleaf Asset Management LLC Purchases 146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) - Defense World
Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections - TipRanks
Tardive Dyskinesia Treatment Market Size, Share & Future - openPR
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions - Simply Wall St
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675 - Marketscreener.com
Neurocrine begins phase 1 study of new neurological drug By Investing.com - Investing.com South Africa
Neurocrine begins phase 1 study of new neurological drug - Investing.com India
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PR Newswire
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors - Simply Wall St
Neurological Disorder Drugs Market Detailed In New Research - openPR
Neurocrine Biosci stock hits 52-week low at $110.92 - Investing.com
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.59 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Illumine Investment Management LLC Invests $1.30 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GW&K Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Los Angeles Capital Management LLC Has $70 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NasdaqGS:NBIX) Highlights INGREZZA's Positive Phase 4 Study Results - Simply Wall St
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Peloton Wealth Strategists - MarketBeat
Phase IV Ingrezza data move focus from sales outlook - The Pharma Letter
NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan
Blackhawk Capital Partners LLC. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):